US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Certara Inc

us-stock
To Invest in {{usstockname}}
us-stock
$9.68 0.0442(4.42%) CERT at 04 Dec 2025 04:28 PM Health Information Services
Lowest Today 9.29
Highest Today 9.695
Today’s Open 9.3
Prev. Close 9.27
52 Week High 15.69
52 Week Low 8.03
Day’s Range: Low 9.29 High 9.695
52-Week Range: Low 8.03 High 15.69
1 day return -
1 Week return +5.89
1 month return -16.16
3 month return -8.45
6 month return -18.87
1 year return -10.8
3 year return -45.31
5 year return -74.44
10 year return -

Institutional Holdings

Wasatch Advisors LP 8.43

BlackRock Inc 8.30

Vanguard Group Inc 7.74

ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 4.91

Dimensional Fund Advisors, Inc. 4.89

iShares Core S&P Small-Cap ETF 4.09

Geneva Capital Management 3.81

Wasatch Core Growth 3.54

Teacher Retirement System Of Texas 3.53

Ameriprise Financial Inc 3.40

Deerfield Management Co 2.44

Vanguard Total Stock Mkt Idx Inv 2.38

State Street Corp 2.28

Vanguard Explorer Inv 2.11

Morgan Stanley - Brokerage Accounts 1.91

Vanguard Small Cap Index 1.84

Brown Brothers Harriman & Co 1.74

CT (Lux) American Smaller Com 9U USD 1.66

Mackenzie Investments 1.65

American Funds SMALLCAP World A 1.34

Capital World Investors 1.34

Wasatch Small Cap Growth Investor 1.30

Canada Life US Small-Mid Cap Growth F 1.26

Geode Capital Management, LLC 1.26

Nationwide Geneva Small Cap Gr Instl Svc 1.24

Royal Bank of Canada 1.11

Vanguard Small Cap Growth Index Inv 1.04

Massachusetts Financial Services Company 1.00

CT American Smaller Coms(US) InstAccGBP 0.95

Marshall Wace Asset Management Ltd 0.94

Glenmede Trust Co NA 0.92

London Company of Virginia 0.92

DFA US Targeted Value I 0.88

Meridian Growth Legacy 0.82

DFA US Small Cap Value I 0.80

Vanguard Institutional Extnd Mkt Idx Tr 0.74

Vanguard VIF Small Co Gr 0.71

Dimensional US Targeted Value ETF 0.68

MFS New Discovery I 0.68

iShares S&P Small-Cap 600 Value ETF 0.64

Market Status

Strong Buy: 4

Buy: 1

Hold: 6

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1476.46 M

PB Ratio 1.3701

PE Ratio 132.4286

Enterprise Value 1588.74 M

Total Assets 1575.10 M

Volume 1385852

Company Financials

Annual Revenue FY24:385148000 385.1M, FY23:352960000 353.0M, FY22:335644000 335.6M, FY21:286104000 286.1M, FY20:243530000 243.5M

Annual Profit FY24:230632000 230.6M, FY23:214222000 214.2M, FY22:203067000 203.1M, FY21:174488000 174.5M, FY20:142765000 142.8M

Annual Net worth FY24:-12051000 -12.1M, FY23:-33727000 -33.7M, FY22:14731000 14.7M, FY21:-13266000 -13.3M, FY20:-49397000 -49.4M

Quarterly Revenue Q3/2025:104616000 104.6M, Q2/2025:104570000 104.6M, Q1/2025:106004000 106.0M, Q3/2024:94820000 94.8M, Q2/2024:93313000 93.3M

Quarterly Profit Q3/2025:50916000 50.9M, Q2/2025:63854000 63.9M, Q1/2025:64483000 64.5M, Q3/2024:57631000 57.6M, Q2/2024:40310000 40.3M

Quarterly Net worth Q3/2025:1525000 1.5M, Q2/2025:-1968000 -2.0M, Q1/2025:4743000 4.7M, Q3/2024:-1371000 -1.4M, Q2/2024:-12574000 -12.6M

Fund house & investment objective

Company Information Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines; Chemaxon Compound Registration, that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Organisation Health Information Services

Employees 1487

Industry Health Information Services

CEO Dr. William F. Feehery Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right